232 phenotypes from 25 alleles in 56 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
ApcGt(XA018)Byg/Apc+ (B6.129P2-ApcGt(XA018)Byg x C3H/HeJ)F1	decreased tumor growth/size	J:202877
ApcGt(XA018)Byg/Apc+ B6.129P2-ApcGt(XA018)Byg	increased colon adenoma incidence	J:202877
	increased intestinal adenoma incidence	J:202877
	increased tumor growth/size	J:202877
	intestine polyps	J:202877
ApcM1Tno/Apc+ either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl)	increased mammary adenocarcinoma incidence	J:218227
	increased mammary gland tumor incidence	J:218227
	increased osteoma incidence	J:218227
	increased osteosarcoma incidence	J:218227
	increased pilomatricoma incidence	J:218227
	increased skin tumor incidence	J:218227
	increased trichoepithelioma incidence	J:218227
	premature death	J:218227
ApcM1Tno/Apc+ involves: C57BL/6 * DBA/2JJcl	increased mammary gland tumor incidence	J:218227
	increased osteoma incidence	J:218227
	increased skin tumor incidence	J:218227
	premature death	J:218227
ApcM1Tno/ApcM1Tno involves: C57BL/6 * DBA/2JJcl	embryonic lethality during organogenesis, complete penetrance	J:218227
ApcMin/Apc+ (AKR/J x C57BL/6J-ApcMin)F1	aneuploidy	J:21369
	decreased intestinal adenoma incidence	J:1879
	extended life span	J:1879
	increased incidence of tumors by chemical induction	J:15101
	increased intestinal adenocarcinoma incidence	J:21369
ApcMin/Apc+ (MA/MyJ x C57BL/6J-ApcMin)F1	decreased intestinal adenoma incidence	J:1879
	extended life span	J:1879
ApcMin/Apc+ B6(AKR)-ApcMin	abnormal pregnancy	J:10209
	anemia	J:10209
	increased intestinal adenocarcinoma incidence	J:10209
	increased intestinal adenoma incidence	J:10209
	increased mammary gland tumor incidence	J:15101
	mammary gland hyperplasia	J:15101
	premature death	J:10209
ApcMin/Apc+ B6.Cg-Brca2tm1Mbn ApcMin	abnormal mammary gland development	J:67445
	abnormal ovarian follicle morphology	J:67445
	abnormal ovarian folliculogenesis	J:67445
	abnormal vagina epithelium morphology	J:67445
	absent corpus luteum	J:67445
	absent mature ovarian follicles	J:67445
	absent nipple	J:67445
	adrenal gland hyperplasia	J:67445
	decreased body weight	J:67445
	increased incidence of induced tumors	J:67445
	increased mammary gland tumor incidence	J:67445
	ovary atrophy	J:67445
	normal reproductive system phenotype	J:67445
	uterus atrophy	J:67445
ApcMin/Apc+ C57BL/6J-ApcMin	decreased macrophage cell number	J:85142
	hepatic steatosis	J:86036
	increased circulating free fatty acids level	J:86036
	increased circulating triglyceride level	J:86036
	increased colon adenoma incidence	J:158733, J:160399
	increased intestinal adenoma incidence	J:1879, J:85142, J:158733, J:241611
	increased prostaglandin level	J:85142
	postnatal growth retardation	J:85142
	premature death	J:1879
ApcMin/Apc+ C57BL/6J-ApcMin/J	abnormal interleukin secretion	J:305794
ApcMin/Apc+ involves: 129 * C57BL/6	decreased NK cell number	J:156864
	decreased splenocyte number	J:156864
	decreased T cell number	J:156864
	intestine polyps	J:156864
ApcMin/Apc+ involves: 129P2/OlaHsd * C57BL/6	increased intestinal adenoma incidence	J:95893
	normal neoplasm	J:95893
ApcMin/Apc+ involves: AKR/J * C57BL/6J	anemia	J:10209
	decreased hematocrit	J:10209
	hyperlipidemia	J:10209
	increased intestinal adenocarcinoma incidence	J:10209
	increased intestinal adenoma incidence	J:10209
	melena	J:10209
	premature death	J:10209
ApcMin/Apc+ involves: C57BL/6 * C57BL/6J	intestine polyps	J:134087
	premature death	J:134087
ApcMin/Apc+ involves: C57BL/6J	abnormal enterocyte proliferation	J:118600
	abnormal intestinal goblet cell morphology	J:118600
	abnormal intestinal mucosa morphology	J:118600
	abnormal large intestine crypts of Lieberkuhn morphology	J:118600
	abnormal tumor pathology	J:268691
	anemia	J:75393
	decreased intestinal adenoma incidence	J:268691
	decreased tumor growth/size	J:268691
	increased intestinal adenoma incidence	J:75393, J:94108, J:299895
	increased mammary adenocarcinoma incidence	J:94108
	intestinal obstruction	J:75393
	intestine polyps	J:191217
	premature death	J:75393, J:94108
	rectal prolapse	J:94108
ApcMin/Apc+ Tg(Rorc-EGFP)1Ebe/? involves: C57BL/6	abnormal effector T cell morphology	J:137020
	colon polyps	J:137020
	enlarged mesenteric lymph nodes	J:137020
	intestine polyps	J:137020
	lymph node hyperplasia	J:137020
ApcMin/ApcMin involves: AKR/J * C57BL/6J	abnormal egg cylinder morphology	J:27993
	abnormal embryo development	J:27993
	abnormal embryo size	J:27993
ApcMin/ApcMin involves: C57BL/6 * POMOD	abnormal embryo development	J:27993
	decreased embryo size	J:27993
	embryonic lethality between implantation and placentation	J:27993
	embryonic lethality, complete penetrance	J:27993
ApcMin/ApcMin involves: C57BL/6J	abnormal cell physiology	J:187862
ApcMin/ApcMin involves: C57BL/6J * CAST/EiJ	embryonic lethality, complete penetrance	J:27993
ApcMin/Apctm1.1Klne B6.Cg-ApcMin/Apctm1.1Klne	abnormal enterocyte proliferation	J:186132
	intestine polyps	J:186132
ApcMin/Apctm1Tno involves: 129 * 129S4/SvJae * C57BL/6	abnormal brain development	J:156864
	absent forebrain	J:156864
	absent mandible	J:156864
	absent midbrain	J:156864
	acrania	J:156864
	lethality throughout fetal growth and development, incomplete penetrance	J:156864
	perinatal lethality, complete penetrance	J:156864
Apctm1.1Alew/Apc+ B6.129-Apctm1.1Alew	abnormal tumor morphology	J:180275
	anemia	J:180275
	gastrointestinal tract polyps	J:180057, J:180275
	increased adenoma incidence	J:180057
	increased apoptosis	J:180275
	increased cell proliferation	J:180275
	increased intestinal adenoma incidence	J:180057, J:180275
	premature death	J:180275
Apctm1.1Alew/Apctm1.1Alew B6.129-Apctm1.1Alew	prenatal lethality, complete penetrance	J:180057
Apctm1.1Klne/Apctm1.1Klne B6.129-Apctm1.1Klne	abnormal enterocyte proliferation	J:186132
	colon polyps	J:186132
	gastric polyps	J:186132
Apctm1.1Rsmi/Apc+ involves: 129P2/OlaHsd	increased gastrointestinal tumor incidence	J:149225
Apctm1.1Rsmi/Apc+ involves: 129P2/OlaHsd * C57BL/6 * FVB/N	anemia	J:159883
	increased desmoid tumor incidence	J:159883
	increased gastrointestinal tumor incidence	J:159883
	increased intestinal adenoma incidence	J:159883
	increased large intestine adenocarcinoma incidence	J:159883
	increased small intestine adenocarcinoma incidence	J:159883
	intestinal obstruction	J:159883
	premature death	J:159883
	skin cyst	J:159883
Apctm1.1Tno/Apc+ involves: 129S4/SvJae * C57BL/6	anemia	J:127452
	gastrointestinal hemorrhage	J:127452
	increased intestinal adenoma incidence	J:127452
	intestinal obstruction	J:127452
	intestine polyps	J:127452
	premature death	J:127452
Apctm1.1Tno/Apctm1Tno involves: 129 * 129S4/SvJae * BALB/cJ * C57BL/6	abnormal brain development	J:156864
	absent forebrain	J:156864
	absent mandible	J:156864
	absent midbrain	J:156864
	acrania	J:156864
	perinatal lethality, complete penetrance	J:156864
Apctm1.1Tyj/Apc+ involves: 129S4/SvJaeSor * C57BL/6	anemia	J:160399
	increased colon adenoma incidence	J:160399
	increased intestinal adenoma incidence	J:160399
	increased tumor growth/size	J:160399
	premature death	J:160399
Apctm1Cip/Apc+ involves: 129P2/OlaHsd * C57BL/6	anemia	J:94108
	increased colon adenoma incidence	J:94108
	increased intestinal adenocarcinoma incidence	J:94108
	increased intestinal adenoma incidence	J:94108
	increased mammary adenocarcinoma incidence	J:94108
	premature death	J:94108
	rectal hemorrhage	J:94108
	rectal prolapse	J:94108
Apctm1Cip/Apctm1Cip involves: 129P2/OlaHsd * C57BL/6	prenatal lethality, complete penetrance	J:94108
Apctm1Kk/Apctm1Kk Tg(Lck-cre)1Cwi/? involves: 129S6/SvEvTac * C57BL/6 * DBA/2	abnormal intestinal mucosa morphology	J:104334
	abnormal T cell differentiation	J:100461
	arrested T cell differentiation	J:100461
	increased circulating tumor necrosis factor level	J:128606
	increased double-negative T cell number	J:100461
	increased intestinal adenoma incidence	J:104334
	increased mast cell number	J:128606
	intestine polyps	J:128606
	small thymus	J:100461
	thymus hypoplasia	J:100461
Apctm1Mmt/Apc+ involves: 129S2/SvPas * C57BL/6J	increased intestinal adenoma incidence	J:25200, J:79668
	intestine polyps	J:79668
Apctm1Mmt/Apctm1Mmt involves: 129S2/SvPas * C57BL/6J	embryonic lethality between implantation and somite formation, incomplete penetrance	J:25200
Apctm1Rak/Apc+ (C57BL/6J x 129P2/OlaHsd)F1	epidermal cyst	J:151494
	increased desmoid tumor incidence	J:151494
	increased gastrointestinal tumor incidence	J:151494
	increased stomach tumor incidence	J:151494
	premature death	J:151494
Apctm1Rak/Apc+ B6.129P2-Apctm1Rak	colon polyps	J:107273
	decreased tumor-free survival time	J:107273
	gastric polyps	J:107273
	intestine polyps	J:107273
Apctm1Rak/Apc+ involves: 129P2/OlaHsd * C57BL/6	increased hepatocellular carcinoma incidence	J:20443
	increased intestinal adenocarcinoma incidence	J:20443
	increased intestinal adenoma incidence	J:20443
	premature death	J:20443
	rectal hemorrhage	J:20443
Apctm1Rak/Apc+ involves: 129P2/OlaHsd * C57BL/6J	increased intestinal adenocarcinoma incidence	J:65142
	increased stomach tumor incidence	J:65142
Apctm1Rak/Apctm1Rak involves: 129P2/OlaHsd * C57BL/6	embryonic lethality, complete penetrance	J:20443
Apctm1Rfo/Apctm1Rfo B6.129P2-Apctm1Rfo	postnatal lethality, incomplete penetrance	J:55416
Apctm1Rfo/Apctm1Rfo involves: 129P2/OlaHsd	normal cellular phenotype	J:116121
Apctm1Rfo/Apctm1Rfo involves: 129P2/OlaHsd * C57BL/6J	absent male preputial gland	J:55416
	decreased body size	J:55416
	normal mortality/aging	J:55416
	normal neoplasm	J:55416
	postnatal growth retardation	J:55416
	skin cyst	J:55416
Apctm1Rsmi/Apc+ Tg(Fabp1-cre)1Jig/0 involves: 129P2/OlaHsd * FVB/N	increased gastrointestinal tumor incidence	J:159883
	increased intestinal adenocarcinoma incidence	J:159883
	increased intestinal adenoma incidence	J:159883
	increased large intestine adenocarcinoma incidence	J:159883
	increased small intestine adenocarcinoma incidence	J:159883
	increased tumor-free survival time	J:159883
Apctm1Rsmi/Apctm1Rsmi involves: 129P2/OlaHsd	normal neoplasm	J:149225
	no abnormal phenotype detected	J:149225
Apctm1Rsmi/Apctm1Rsmi Pgrtm2(cre)Lyd/Pgr+ involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J	abnormal internal female genitalia morphology	J:210095
	abnormal oviduct morphology	J:210095
	endometrium hyperplasia	J:210095
	increased granulosa cell tumor incidence	J:210095
	increased ovary tumor incidence	J:210095
	increased reproductive system tumor incidence	J:210095
	ovary cyst	J:210095
Apctm1Rsmi/Apctm1Rsmi Tg(Col2a1-cre)1Rsjo/0 involves: 129P2/OlaHsd * FVB/N	abnormal abdominal wall morphology	J:149225
	abnormal bone mineralization	J:149225
	abnormal cartilage development	J:149225
	abnormal chondrocyte morphology	J:149225
	abnormal craniofacial morphology	J:149225
	abnormal cranium morphology	J:149225
	abnormal endochondral bone ossification	J:149225
	abnormal forelimb morphology	J:149225
	abnormal hindlimb morphology	J:149225
	abnormal humerus morphology	J:149225
	abnormal limb development	J:149225
	abnormal mandible morphology	J:149225
	abnormal rib morphology	J:149225
	abnormal skeleton development	J:149225
	abnormal thoracic cavity morphology	J:149225
	absent sternum	J:149225
	blistering	J:149225
	decreased body length	J:149225
	decreased fetal size	J:149225
	enhanced osteoblast differentiation	J:149225
	perinatal lethality, incomplete penetrance	J:149225
	postnatal lethality, complete penetrance	J:149225
	scapular bone hypoplasia	J:149225
	short forelimb	J:149225
	short hindlimb	J:149225
	short ribs	J:149225
Apctm1Tno/Apc+ involves: 129 * 129S4/SvJae * C57BL/6	increased hepatocellular carcinoma incidence	J:156864
Apctm1Tno/Apc+ Tg(Vil1-cre)997Gum/0 involves: 129S4/SvJae * C57BL/6 * SJL	anemia	J:126018
	increased gastrointestinal tumor incidence	J:126018
	increased small intestine adenocarcinoma incidence	J:126018
	postnatal growth retardation	J:126018
Apctm1Tno/Apc+ Tg(CDX2-cre)101Erf/0 involves: 129S4/SvJae * C57BL/6 * SJL	anemia	J:126018
	decreased body weight	J:126018
	decreased hematocrit	J:126018
	increased gastrointestinal tumor incidence	J:126018
	increased mammary adenocarcinoma incidence	J:126018
	increased tumor incidence	J:126018
	intestinal obstruction	J:126018
	premature death	J:126018
	rectal prolapse	J:126018
Apctm1Tno/Apc+ Tg(CDX2-cre*)189Erf/0 involves: 129S4/SvJae * C57BL/6 * SJL	normal neoplasm	J:148161
Apctm1Tno/Apc+ Tg(CDX2-cre/ERT)#Erf/0 involves: 129S4/SvJae	increased gastrointestinal tumor incidence	J:189226
Apctm1Tno/Apctm1Tno involves: 129 * 129S4/SvJae * C57BL/6	increased hepatocellular carcinoma incidence	J:156864
	increased incidence of tumors by chemical induction	J:156864
Apctm1Tno/Apctm1Tno involves: 129S4/SvJae * C57BL/6	increased colon adenoma incidence	J:43301
Apctm1Tno/Apctm1Tno Lgr5tm1(cre/ERT2)Cle/Lgr5+ involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	increased intestinal adenoma incidence	J:227334
Apctm1Tno/Apctm1Tno Tg(Cdh16-cre)91Igr/0 involves: 129S4/SvJae * ICR	decreased body weight	J:95502
	enlarged kidney	J:95502
	increased blood urea nitrogen level	J:95502
	increased renal cystadenoma incidence	J:95502
	kidney cyst	J:95502
	polycystic kidney	J:95502
	postnatal lethality, incomplete penetrance	J:95502
	premature death	J:95502
Apctm1Tno/Apctm1Tno Tg(CDX2-cre)101Erf/0 involves: 129S4/SvJae * C57BL/6 * SJL	embryonic lethality, complete penetrance	J:126018
Apctm1Tno/Apctm1Tno Tg(CDX2-cre*)189Erf/0 involves: 129S4/SvJae * C57BL/6 * SJL	increased colon adenoma incidence	J:148161
	intestine polyps	J:148161
	kinked tail	J:148161
	postnatal lethality, complete penetrance	J:148161
	premature death	J:148161
	short tail	J:148161
Apctm1Tno/Apctm1Tno Tg(Cyp1a1-cre/ERT)1Dwi/0 involves: 129S4/SvJae * C57BL/6 * CBA	abnormal urinary bladder urothelium morphology	J:164579
Apctm1Tno/Apctm1Tno Tg(Pbsn-cre)4Prb/0 involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2	increased prostate gland adenocarcinoma incidence	J:120308
	increased prostate intraepithelial neoplasia incidence	J:120308
	increased tumor incidence	J:120308
	premature death	J:120308
	prostate gland epithelial hyperplasia	J:120308
Apctm1Tno/Apctm1Tno Tg(Vil1-cre)997Gum/0 involves: 129S4/SvJae * C57BL/6 * SJL	embryonic lethality, complete penetrance	J:126018
Apctm1Tyj/Apc+ Tg(Vil1-cre)20Syr/0 involves: C57BL/6 * DBA/2	increased colon adenoma incidence	J:160399
	increased intestinal adenoma incidence	J:160399
Apctm1Tyj/Apctm1Tyj involves: 129P2/OlaHsd * C57BL/6	no abnormal phenotype detected	J:159014
Apctm2.1Alew/Apc+ B6.129-Apctm2.1Alew	abnormal tumor pathology	J:180057
	anemia	J:180057
	gastrointestinal tract polyps	J:180057
	hunched posture	J:180057
	increased adenoma incidence	J:180057
	increased intestinal adenoma incidence	J:180057
Apctm2.1Alew/Apctm2.1Alew B6.129-Apctm2.1Alew	prenatal lethality, complete penetrance	J:180057
Apctm2.1Cip/Apc+ Tg(Fabp1-cre)1Jig/0 involves: 129P2/OlaHsd * FVB/N	increased intestinal adenocarcinoma incidence	J:132357
Apctm2.1Cip/Apc+ Tg(Vil1-cre)20Syr/0 involves: 129P2/OlaHsd * C57BL/6 * DBA/2	increased colon adenoma incidence	J:160399
	increased intestinal adenoma incidence	J:160399
Apctm2.1Cip/Apc+ Tg(Vil1-cre/ERT2)23Syr/0 involves: 129P2/OlaHsd * C57BL/6 * DBA/2	abnormal autophagy	J:227287
	abnormal gut flora balance	J:227287
	cachexia	J:227287
	decreased tumor-free survival time	J:227287
	increased colon adenoma incidence	J:227287
	increased intestinal adenoma incidence	J:227287
	intestine polyps	J:227287
	rectal prolapse	J:227287
Apctm2.1Cip/Apc+ Lgr5tm1(cre/ERT2)Cle/Lgr5+ involves: 129P2/OlaHsd * C57BL/6	normal neoplasm	J:186084
Apctm2.1Cip/Apc+ Lrig1tm1.1(cre/ERT2)Rjc/Lrig1+ involves: 129 * 129P2/OlaHsd * C57BL/6	increased intestinal adenoma incidence	J:186084
Apctm2.1Cip/Apctm2.1Cip involves: 129P2/OlaHsd * C57BL/6N	increased hepatocellular carcinoma incidence	J:94721
	liver hyperplasia	J:94721
	premature death	J:94721
Apctm2.1Cip/Apctm2.1Cip Tg(Ttr-cre/Esr1*)1Vco/0 B6.Cg-Apctm2.1Cip Tg(Ttr-cre/Esr1*)1Vco	abnormal liver morphology	J:184496
	abnormal NK T cell physiology	J:184496
	decreased NK T cell number	J:184496
	enlarged liver	J:184496
	increased interferon-gamma secretion	J:184496
	increased interleukin-4 secretion	J:184496
	liver inflammation	J:184496
Apctm2.1Cip/Apctm2.1Cip Tg(Vil1-cre/ERT2)23Syr/0 involves: 129P2/OlaHsd * C57BL/6 * DBA/2	abnormal colon morphology	J:98469
	abnormal intestinal epithelium morphology	J:98469
	abnormal intestinal goblet cell morphology	J:98469
	abnormal intestine development	J:98469
	abnormal small intestine crypts of Lieberkuhn morphology	J:98469
	increased small intestinal crypt cell apoptosis	J:98469
	premature death	J:98469
Apctm2.1Rak/Apc+ involves: 129/Sv * C57BL/6J * SJL	abnormal nursing	J:114152
	anemia	J:114152
	increased gastrointestinal tumor incidence	J:114152
	increased intestinal adenoma incidence	J:114152
	premature death	J:114152
	rectal hemorrhage	J:114152
Apctm2Mmt/Apc+ involves: 129X1/SvJ	increased intestinal adenoma incidence	J:81402
Apctm2Mmt/Apctm2Mmt involves: 129X1/SvJ	embryonic lethality	J:81402
Apctm2Mmt/Apctm3Mmt involves: 129X1/SvJ * C57BL/6N	abnormal egg cylinder morphology	J:81402
	abnormal embryonic epiblast morphology	J:81402
	abnormal embryonic tissue morphology	J:81402
Apctm2Rak/Apc+ Tg(Car1-cre)5Flt/0 involves: 129/Sv * C57BL/6J * SJL	abnormal feces composition	J:164247
	anemia	J:164247
	colon polyps	J:164247
	decreased hematocrit	J:164247
	normal homeostasis/metabolism phenotype	J:164247
	increased incidence of tumors by chemical induction	J:164247
	increased intestinal adenoma incidence	J:164247
	normal neoplasm	J:164247
Apctm2Rak/Apctm2.1Rak involves: 129/Sv * C57BL/6J * SJL	no abnormal phenotype detected	J:114152
Apctm2Rak/Apctm2Rak involves: 129/Sv * C57BL/6J * SJL	increased carcinoma incidence	J:156532
	increased colon adenoma incidence	J:156532
	increased organ/body region tumor incidence	J:156532
Apctm2Rak/Apctm2Rak Tg(Car1-cre)5Flt/0 involves: 129/Sv * C57BL/6J * SJL	decreased body weight	J:164247
	decreased hematocrit	J:164247
	increased intestinal adenoma incidence	J:164247
	premature death	J:164247
	rectal prolapse	J:164247
Apctm2Rak/Apctm2Rak Tg(KRT14-cre)8Brn/0 involves: 129/Sv * C57BL/6J * FVB/N * SJL	abnormal cell proliferation	J:114152
	abnormal ear shape	J:114152
	abnormal hair follicle bulb morphology	J:114152
	abnormal hair follicle development	J:114152
	abnormal hair follicle morphology	J:114152
	abnormal hair follicle orientation	J:114152
	abnormal Hassall's corpuscle morphology	J:114152
	abnormal keratinocyte differentiation	J:114152
	abnormal skin pigmentation	J:114152
	abnormal thymus morphology	J:114152
	abnormal tooth development	J:114152
	absent teeth	J:114152
	absent upper incisors	J:114152
	blepharoptosis	J:114152
	corneal epithelium hyperplasia	J:114152
	decreased body size	J:114152
	decreased thymocyte number	J:114152
	delayed hair appearance	J:114152
	Harderian gland hyperplasia	J:114152
	increased ear pigmentation	J:114152
	increased forehead pigmentation	J:114152
	lethargy	J:114152
	postnatal lethality, complete penetrance	J:114152
	salivary gland epithelial hyperplasia	J:114152
	scaly skin	J:114152
	short hair	J:114152
	short vibrissae	J:114152
	skin ridges	J:114152
	small stomach	J:114152
	small thymus	J:114152
	underdeveloped hair follicles	J:114152
	weight loss	J:114152
	wrinkled skin	J:114152
Apctm2Rak/Apctm2Rak Tg(Pdx1-cre)6Tuv/0 involves: 129/Sv * C57BL/6J * FVB/N * SJL	abnormal intestine development	J:234310
	abnormal pancreas development	J:234310
	decreased pancreatic beta cell mass	J:234310
	decreased pancreatic islet number	J:234310
	duodenal atresia	J:234310
	neonatal lethality, complete penetrance	J:234310
Apctm2Rfo/Apc+ 129P2/OlaHsd-Apctm2Rfo	increased gastrointestinal tumor incidence	J:151494
	increased liver tumor incidence	J:151494
	increased mammary adenocarcinoma incidence	J:151494
	premature death	J:151494
Apctm2Rfo/Apc+ (C57BL/6J x 129P2/OlaHsd)F1	epidermal cyst	J:151494
	increased desmoid tumor incidence	J:151494
	increased liver tumor incidence	J:151494
	increased mammary adenocarcinoma incidence	J:151494, J:204440
	increased mammary gland tumor incidence	J:151494
	increased metastatic potential	J:204440
	increased tumor incidence	J:151494
	premature death	J:151494
Apctm2Rfo/Apc+ B6.129P2-Apctm2Rfo	increased liver tumor incidence	J:151494
	increased mammary adenocarcinoma incidence	J:151494
	increased mammary gland tumor incidence	J:151494
	premature death	J:151494
Apctm2Rfo/Apctm2Rfo B6.129P2-Apctm2Rfo	postnatal lethality, complete penetrance	J:151494
Apctm2Tno/Apc+ involves: C57BL/6J	hepatic steatosis	J:86036
	hyperlipidemia	J:86036
	increased circulating cholesterol level	J:86036
	increased circulating free fatty acids level	J:86036
	increased circulating triglyceride level	J:86036
	intestine polyps	J:86036
Apctm2Tno/Apc+ Not Specified	increased intestinal adenoma incidence	J:47857
	premature death	J:47857
Apctm3Mmt/Apc+ B6.129X1-Apctm3Mmt	increased intestinal adenoma incidence	J:101604
	intestine polyps	J:101604
Apctm3Mmt/Apc+ involves: 129X1/SvJ * C57BL/6N	intestine polyps	J:81402
Apctm3Mmt/Apctm3Mmt involves: 129X1/SvJ * C57BL/6N	abnormal anterior visceral endoderm morphology	J:81402
	abnormal brain development	J:81402
	abnormal developmental patterning	J:81402
	abnormal endocardial heart tube morphology	J:81402
	abnormal floor plate morphology	J:81402
	abnormal foregut morphology	J:81402
	abnormal head development	J:81402
	abnormal hindbrain development	J:81402
	abnormal mesendoderm development	J:81402
	abnormal neural tube morphology	J:81402
	abnormal primitive node morphology	J:81402
	absent forebrain	J:81402
	absent midbrain	J:81402
	absent neural folds	J:81402
	cardia bifida	J:81402
	embryonic lethality during organogenesis, complete penetrance	J:81402
	embryonic-extraembryonic boundary constriction	J:81402
	incomplete embryo turning	J:81402
	rostral body truncation	J:81402
	rostral-caudal axis duplication	J:81402
	split notochord	J:81402
Apctm4Mmt/Apc+ B6.129X1-Apctm4Mmt	increased intestinal adenoma incidence	J:101604
	intestine polyps	J:101604
Apctm4Mmt/Apctm4Mmt B6.129X1-Apctm4Mmt	embryonic lethality during organogenesis, complete penetrance	J:101604